EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study

Joon Sung Kim iD, Weonjin Ko, Jun-Won Chung, Tae Ho Kim

Helicobacter · 2023-06 · 28 (3)

DOI: 10.1111/hel.12977 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, online erschienen am 21.04.2023. Verfasst von Joon Sung Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Se…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HK innoN Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bismuth‐based quadruple therapy (BQT) is recommended as the first‐line empirical therapy for Helicobacter pylori eradication as it is not associated with resistance. However, few studies have investigated the use of potassium‐competitive acid blockers for BQT.

Aim

To investigate the efficacy and safety profiles of tegoprazan‐based BQT (TBMT) versus lansoprazole‐based BQT (LBMT) for H . pylori eradication.

Methods

We included patients older than 18 with an H . pylori infection without a history of H . pylori eradication who visited four university‐affiliated hospitals between March 2020 and December 2021. H . pylori infection was diagnosed using a rapid urease test or Giemsa staining. Patients were randomly assigned to the TBMT or LBMT group.

Results

217 subjects were randomly allocated to receive either TBMT ( n = 108) or LBMT ( n = 109) therapy. Intention‐to‐treat (ITT) eradication rates of TBMT and LBMT were 80.0% and 77.4% (95% confidence interval [CI]: −8.4 to 13.7, p = 0.0124), respectively. Corresponding modified ITT rates were 90.3% and 84.5% (95% CI: −3.6 to 15.2, p = 0.0005), respectively. Per‐protocol (PP) eradication rates of TBMT and LBMT were 90.2% and 82.4% (95% CI: −2.5 to 18.2, p = 0.0003), respectively. There was no significant difference in the rate of adverse events between the TBMT and LBMT groups (39.1% vs. 43.4%, p = 0.5211). TBMT showed higher eradication rates than that of LBMT in ITT, m‐ITT, and PP analysis.

Conclusion

TBMT showed a noninferior eradication rate and similar adverse events to LBMT as a first‐line eradication regimen. Our results suggest that tegoprazan might be substituted for proton pump inhibitors in H . pylori eradication regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriHumansBismuthAnti-Bacterial AgentsProton Pump InhibitorsDrug Therapy, CombinationTreatment OutcomeAmoxicillinBenzene DerivativesImidazoles

Stichwörter der Autor:innen

Helicobacter pyloriTegoprazanpotassium-competitive acid blocker

Substanzen

BismuthAnti-Bacterial AgentsProton Pump InhibitorsAmoxicillintegoprazanBenzene DerivativesImidazoles

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, South Korea.
  • Divison of Gastroenterology, Department of Internal Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

ORCID-Profile: Joon Sung Kim

Förderung

  • HK innoN Corp

Zitieren

APA

Kim, J. S., Ko, W., Chung, J. W., & Kim, T. H. (2023). Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter, 28(3). https://doi.org/10.1111/hel.12977

Vancouver

Kim JS, Ko W, Chung JW, Kim TH. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter. 2023;28(3). doi:10.1111/hel.12977

BibTeX
@article{Kim2023,
  author = {Kim, Joon Sung and Ko, Weonjin and Chung, Jun-Won and Kim, Tae Ho},
  title = {Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study},
  journal = {Helicobacter},
  year = {2023},
  volume = {28},
  number = {3},
  doi = {10.1111/hel.12977}
}
Kostenlos starten →